Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
6
|
| pubmed:dateCreated |
1998-7-22
|
| pubmed:abstractText |
3F8 is an IgG3 murine monoclonal antibody directed against the ganglioside GD2. In a phase II study, 3F8 was administered i.v. to 16 patients (pts) who had stage 4 neuroblastoma. Response was seen in bony lesions (2 of 7 pts) and marrow (3 of 8 pts). Acute toxicities of pain, fever, urticaria, hypertension, hypotension and anaphylactoid reactions were self-limited and manageable. Three pts are long-term survivors between 79-130+ months after 3F8 treatment without additional systemic therapy and no delayed neurological complications. The potential benefits of 3F8 when added to chemoradio-therapy warrant further investigation.
|
| pubmed:grant | |
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical | |
| pubmed:status |
MEDLINE
|
| pubmed:month |
Jun
|
| pubmed:issn |
1019-6439
|
| pubmed:author | |
| pubmed:issnType |
Print
|
| pubmed:volume |
12
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
1299-306
|
| pubmed:dateRevised |
2007-11-14
|
| pubmed:meshHeading |
pubmed-meshheading:9592190-Abdominal Pain,
pubmed-meshheading:9592190-Adolescent,
pubmed-meshheading:9592190-Antibodies, Monoclonal,
pubmed-meshheading:9592190-Antibody Formation,
pubmed-meshheading:9592190-Antineoplastic Agents,
pubmed-meshheading:9592190-Child,
pubmed-meshheading:9592190-Child, Preschool,
pubmed-meshheading:9592190-Fever,
pubmed-meshheading:9592190-Gangliosides,
pubmed-meshheading:9592190-Humans,
pubmed-meshheading:9592190-Hypertension,
pubmed-meshheading:9592190-Hypotension,
pubmed-meshheading:9592190-Immunotherapy,
pubmed-meshheading:9592190-Infant,
pubmed-meshheading:9592190-Infant, Newborn,
pubmed-meshheading:9592190-Neuroblastoma,
pubmed-meshheading:9592190-Respiration Disorders,
pubmed-meshheading:9592190-Treatment Outcome,
pubmed-meshheading:9592190-Urticaria
|
| pubmed:year |
1998
|
| pubmed:articleTitle |
3F8 monoclonal antibody treatment of patients with stage 4 neuroblastoma: a phase II study.
|
| pubmed:affiliation |
Department of Pediatrics, Memorial Sloan-Kettering Cancer Center, New York, NY 10021, USA.
|
| pubmed:publicationType |
Journal Article,
Clinical Trial,
Research Support, U.S. Gov't, P.H.S.,
Research Support, Non-U.S. Gov't,
Clinical Trial, Phase II
|